Please assess the completion status of the following clinical trial:

Trial Title: Use of a Calcium Channel Blocker to Prevent Premature Luteinizing Hormone Surges in Infertility Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Infertility requiring intrauterine insemination~* Age: 25-40 (at time of enrollment)~* Intact Normal Ovaries (Both)~* Early follicular phase (day 2-4) serum FSH level \< 20 mIU/ml~* Diagnosis of infertility with a recommended treatment of ovarian stimulation and IUI~Exclusion Criteria:~* BMI \> 38 kg/m2~* Early follicular phase (day 2-4) serum FSH level ≥ 20 mIU/ml~* Overstimulated cycle: \>3 mature follicles (≥17 mm)~* Abnormal uterine cavity and /or tubal blockage~* Diagnosis of infertility with a clear indication for IVF~* Severe male factor infertility: Total Motile Sperm Count \< 2x106 post washing

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Nimodipine (Type: EXPERIMENTAL): Nimodipine 30 mg tablets will be self-administered by the subjects every 6 hours starting on the day that the ultrasound criterion for hCG triggering is met. The tablets will be taken for two days or until an LH surge is detected, whichever comes first. If no LH surge by 2 days, the hCG trigger (250 micrograms recombinant hCG) will be given followed by intrauterine insemination (IUI)in 40 hours. If the LH surge is detected, hCG will be given immediately and two IUIs will be performed 24 hours apart.
- Placebo (Type: PLACEBO_COMPARATOR): Same as for nimodipine but an identical placebo will be self-administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).